ロード中...
Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity
Discrepancies between HIV-1 RNA results assayed by different FDA-approved platforms have been reported. Plasma samples collected from 332 randomly selected clinical trial participants during the second year of antiretroviral treatment were assayed with three FDA-approved platforms: UltraSensitive Ro...
保存先:
| 出版年: | J Clin Microbiol |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society for Microbiology
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4508432/ https://ncbi.nlm.nih.gov/pubmed/26063861 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JCM.00801-15 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|